Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Itzykson

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Blood|June 9, 2012
MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterationsIléana Antony-Debré, Dominique Bluteau, Raphael Itzykson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2020
Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?Mathilde Ruggiu, Bruno Cassinat, Jean-Jacques Kiladjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2012
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidineUwe Platzbecker, Johannes Schetelig, Jürgen Finke, et al.
American Journal of Hematology|June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalitiesAnne Wanquet, Thomas Prebet, Céline Berthon, et al.
Journal of the American Society of Nephrology : JASN|May 6, 2022
Tumor Lysis Syndrome and AKI: Beyond Crystal MechanismsMarine Arnaud, Maud Loiselle, Camille Vaganay, et al.
Blood Cancer Journal|June 13, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA studyPierre Hirsch, Jérôme Lambert, Maxime Bucci, et al.
BMC Bioinformatics|October 28, 2022
Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3rAugustin Boudry, Sasha Darmon, Nicolas Duployez, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Novel M-component based biomarkers in Waldenström's macroglobulinemiaXavier Leleu, Efstathios Koulieris, Dimitrios Maltezas, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Blood|June 9, 2012
MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterationsIléana Antony-Debré, Dominique Bluteau, Raphael Itzykson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2011
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failureThomas Prébet, Steven D Gore, Benjamin Esterni, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2020
Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?Mathilde Ruggiu, Bruno Cassinat, Jean-Jacques Kiladjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2012
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidineUwe Platzbecker, Johannes Schetelig, Jürgen Finke, et al.
American Journal of Hematology|June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalitiesAnne Wanquet, Thomas Prebet, Céline Berthon, et al.
Journal of the American Society of Nephrology : JASN|May 6, 2022
Tumor Lysis Syndrome and AKI: Beyond Crystal MechanismsMarine Arnaud, Maud Loiselle, Camille Vaganay, et al.
Blood Cancer Journal|June 13, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA studyPierre Hirsch, Jérôme Lambert, Maxime Bucci, et al.
BMC Bioinformatics|October 28, 2022
Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3rAugustin Boudry, Sasha Darmon, Nicolas Duployez, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Novel M-component based biomarkers in Waldenström's macroglobulinemiaXavier Leleu, Efstathios Koulieris, Dimitrios Maltezas, et al.
Pageof 10